Cross Time Report: PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens
PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board
PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide
PurMinds NeuroPharma Awarded Synthetic Psilocybin API Import Permit from Health Canada to Develop GMP-Compliant Psychedelic Drug Product Formulations for Clinical Trial Supply
